John A. Spertus MD, MPH , Philip G. Jones MS , Javed Butler MD, MPH, MBA , Suzanne V. Arnold MD, MHA
{"title":"最不重要的堪萨斯城心肌病问卷在心力衰竭严重程度范围内的变化","authors":"John A. Spertus MD, MPH , Philip G. Jones MS , Javed Butler MD, MPH, MBA , Suzanne V. Arnold MD, MHA","doi":"10.1016/j.jchf.2025.102587","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Although the Kansas City Cardiomyopathy Questionnaire (KCCQ) assesses important outcomes for patients with heart failure, whether a 5-point change in KCCQ represents a minimal clinically important difference (MCID) in an individual patient with very poor, as compared with very good, heart failure severity is unknown.</div></div><div><h3>Objectives</h3><div>This study aims to define MCIDs for the KCCQ–Overall Summary Score (OSS) and KCCQ–Clinical Summary Score (CSS) across the range of baseline health status.</div></div><div><h3>Methods</h3><div>Outpatients with heart failure with ejection fractions ≤40% recruited from 14 clinics completed KCCQs at baseline and 6 ± 2 weeks later, along with a 15-point Likert scale assessing their perceived changes in health status. Linear regression estimated MCIDs for small but important changes across the range of baseline KCCQ scores.</div></div><div><h3>Results</h3><div>Among 467 participants (aged 61 ± 13 years, 75% men, left ventricular ejection fraction 25% ± 8%, baseline KCCQ-OSS 61.0 ± 23.7), 28 reported moderate/large deteriorations, 28 small but important deteriorations, 293 no change, 35 small but important improvements, and 83 moderate/large improvements. Although MCIDs for improvement were slightly smaller, with higher baseline scores (6.0 [95% CI: 3.8-8.3] for a baseline KCCQ of 20 vs 2.1 [95% CI: −0.0 to 4.5] for 95; <em>P</em>-trend = 0.003), MCIDs for deterioration were constant (<em>P =</em> 0.87). The overall KCCQ-OSS MCIDs for improvement or deterioration was 3.9 (95% CI: 2.7-5.4), with similar results for the KCCQ-CSS.</div></div><div><h3>Conclusions</h3><div>A 5-point difference in KCCQ scores represents an important clinical change for patients, regardless of their baseline health status, and can be applied to both clinical trials and clinical practice.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 9","pages":"Article 102587"},"PeriodicalIF":11.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Minimally Important Kansas City Cardiomyopathy Questionnaire Changes Across the Spectrum of Heart Failure Severity\",\"authors\":\"John A. Spertus MD, MPH , Philip G. Jones MS , Javed Butler MD, MPH, MBA , Suzanne V. Arnold MD, MHA\",\"doi\":\"10.1016/j.jchf.2025.102587\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Although the Kansas City Cardiomyopathy Questionnaire (KCCQ) assesses important outcomes for patients with heart failure, whether a 5-point change in KCCQ represents a minimal clinically important difference (MCID) in an individual patient with very poor, as compared with very good, heart failure severity is unknown.</div></div><div><h3>Objectives</h3><div>This study aims to define MCIDs for the KCCQ–Overall Summary Score (OSS) and KCCQ–Clinical Summary Score (CSS) across the range of baseline health status.</div></div><div><h3>Methods</h3><div>Outpatients with heart failure with ejection fractions ≤40% recruited from 14 clinics completed KCCQs at baseline and 6 ± 2 weeks later, along with a 15-point Likert scale assessing their perceived changes in health status. Linear regression estimated MCIDs for small but important changes across the range of baseline KCCQ scores.</div></div><div><h3>Results</h3><div>Among 467 participants (aged 61 ± 13 years, 75% men, left ventricular ejection fraction 25% ± 8%, baseline KCCQ-OSS 61.0 ± 23.7), 28 reported moderate/large deteriorations, 28 small but important deteriorations, 293 no change, 35 small but important improvements, and 83 moderate/large improvements. Although MCIDs for improvement were slightly smaller, with higher baseline scores (6.0 [95% CI: 3.8-8.3] for a baseline KCCQ of 20 vs 2.1 [95% CI: −0.0 to 4.5] for 95; <em>P</em>-trend = 0.003), MCIDs for deterioration were constant (<em>P =</em> 0.87). The overall KCCQ-OSS MCIDs for improvement or deterioration was 3.9 (95% CI: 2.7-5.4), with similar results for the KCCQ-CSS.</div></div><div><h3>Conclusions</h3><div>A 5-point difference in KCCQ scores represents an important clinical change for patients, regardless of their baseline health status, and can be applied to both clinical trials and clinical practice.</div></div>\",\"PeriodicalId\":14687,\"journal\":{\"name\":\"JACC. Heart failure\",\"volume\":\"13 9\",\"pages\":\"Article 102587\"},\"PeriodicalIF\":11.8000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JACC. Heart failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213177925005153\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Heart failure","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213177925005153","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Minimally Important Kansas City Cardiomyopathy Questionnaire Changes Across the Spectrum of Heart Failure Severity
Background
Although the Kansas City Cardiomyopathy Questionnaire (KCCQ) assesses important outcomes for patients with heart failure, whether a 5-point change in KCCQ represents a minimal clinically important difference (MCID) in an individual patient with very poor, as compared with very good, heart failure severity is unknown.
Objectives
This study aims to define MCIDs for the KCCQ–Overall Summary Score (OSS) and KCCQ–Clinical Summary Score (CSS) across the range of baseline health status.
Methods
Outpatients with heart failure with ejection fractions ≤40% recruited from 14 clinics completed KCCQs at baseline and 6 ± 2 weeks later, along with a 15-point Likert scale assessing their perceived changes in health status. Linear regression estimated MCIDs for small but important changes across the range of baseline KCCQ scores.
Results
Among 467 participants (aged 61 ± 13 years, 75% men, left ventricular ejection fraction 25% ± 8%, baseline KCCQ-OSS 61.0 ± 23.7), 28 reported moderate/large deteriorations, 28 small but important deteriorations, 293 no change, 35 small but important improvements, and 83 moderate/large improvements. Although MCIDs for improvement were slightly smaller, with higher baseline scores (6.0 [95% CI: 3.8-8.3] for a baseline KCCQ of 20 vs 2.1 [95% CI: −0.0 to 4.5] for 95; P-trend = 0.003), MCIDs for deterioration were constant (P = 0.87). The overall KCCQ-OSS MCIDs for improvement or deterioration was 3.9 (95% CI: 2.7-5.4), with similar results for the KCCQ-CSS.
Conclusions
A 5-point difference in KCCQ scores represents an important clinical change for patients, regardless of their baseline health status, and can be applied to both clinical trials and clinical practice.
期刊介绍:
JACC: Heart Failure publishes crucial findings on the pathophysiology, diagnosis, treatment, and care of heart failure patients. The goal is to enhance understanding through timely scientific communication on disease, clinical trials, outcomes, and therapeutic advances. The Journal fosters interdisciplinary connections with neuroscience, pulmonary medicine, nephrology, electrophysiology, and surgery related to heart failure. It also covers articles on pharmacogenetics, biomarkers, and metabolomics.